No description
-
2022 (v1)PublicationUploaded on: February 14, 2024
-
2023 (v1)Publication
: Endogenous Cushing's syndrome results from excess glucocorticoid secretion, which leads to a myriad of clinical manifestations, comorbidities, and increased mortality despite treatment. Molecular mechanisms and genetic alterations associated with different causes of Cushing's syndrome have been described in the last decade. Imaging modalities...
Uploaded on: February 13, 2024 -
2023 (v1)Publication
: Endogenous Cushing's syndrome results from excess glucocorticoid secretion, which leads to a myriad of clinical manifestations, comorbidities, and increased mortality despite treatment. Molecular mechanisms and genetic alterations associated with different causes of Cushing's syndrome have been described in the last decade. Imaging modalities...
Uploaded on: February 14, 2024 -
2022 (v1)Publication
No description
Uploaded on: February 4, 2024 -
2022 (v1)Publication
The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-known, in the case of combination treatments,...
Uploaded on: February 14, 2024 -
2024 (v1)Publication
: Somatostatin receptors (SSTs) are widely expressed in pituitary tumors and neuroendocrine neoplasms (NENs) of different origins, i.e., the gastrointestinal tract and the thorax (lungs and thymus, thus representing a well-established target for medical treatment with SST ligands (SRLs). However, response to SRLs is highly heterogeneous between...
Uploaded on: February 4, 2024 -
2019 (v1)Publication
Prolactin-secreting tumours (prolactinomas) represent the most common pituitary tumour type, accounting for 47-66% of functional pituitary tumours. Prolactinomas are usually benign and controllable tumours as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Endogenous somatostatin shows anti-secretory effects in both physiological and pathological settings, as well as inhibitory activity on cell growth. Since somatostatin is not suitable for clinical practice, researchers developed synthetic somatostatin receptor ligands (SRLs) to overcome this limitation. Currently, SRLs represent pivotal tools...
Uploaded on: April 14, 2023 -
2024 (v1)Publication
Background: Syndrome of inappropriate antidiuresis (SIAD) is one of the most frequent causes of euvolemic hyponatremia (serum sodium levels < 135 mEq/L) and it represents more than 35% of hyponatremia cases in hospitalized patients. It is characterized by an inappropriate vasopressin (AVP)/antidiuretic hormone (ADH) secretion, which occurs...
Uploaded on: February 4, 2024